First Hep C protease head-to-head trial pits Medivir's TMC435 against J&J's telaprevir
This article was originally published in Scrip
In what is the first of its kind – and might well be the last - the protease inhibitor drug TMC435 developed by J&J unit Janssen Pharmaceuticals in collaboration with Swedish anti-infectives company Medivir is to begin a first head-to-head of trial of its against Vertex/Johnson & Johnson's approved hepatitis C protease inhibitor, Incivek (telaprevir).
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.